Status:
COMPLETED
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Brief Summary
This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide usi...
Eligibility Criteria
Inclusion
- Diagnosed RA patients.
- ≥18 years of age
- Did not receive previous another biological treatment
Exclusion
- Had previous biological treatment
- Use of etanercept for less than 1 year
Key Trial Info
Start Date :
July 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
1493 Patients enrolled
Trial Details
Trial ID
NCT04428424
Start Date
July 5 2020
End Date
August 30 2020
Last Update
September 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Baghdad, Iraq